Biotech companies publish press releases and poster abstracts that reach nobody outside existing circles. The companies winning mindshare build content engines that make investors, physicians, and partners seek them out.
The Problem
Press releases and abstracts aren't content strategy
Most biotech companies confuse clinical communications with content marketing. Press releases announce milestones. Conference abstracts present data. Neither builds the sustained narrative that keeps your company top-of-mind between major announcements. When your only content is event-driven, you disappear from investor and physician consciousness for months at a time.
Regulatory fear kills content velocity
Medical-legal review processes designed for promotional materials get applied to educational content, throttling output to near zero. Your competitors publish weekly thought leadership while your blog posts sit in review for six weeks. The distinction between promotional claims and educational content is clear in regulation but blurred in practice — and that ambiguity costs you visibility.
Technical depth without commercial framing wastes expert time
Your CSO can explain the science beautifully. But translating that into content that matters to non-scientists — investors evaluating market potential, hospital administrators considering adoption, payers assessing value — requires commercial framing that most biotech teams lack. You end up with content that impresses peers at conferences but generates zero commercial pipeline.
How We Help
Our initial assessment audits your current content against three audiences: investors, physicians, and commercial partners. We map what content exists, what gaps remain, and where competitors are building mindshare that should belong to you. Most biotech companies discover they have extensive clinical content but zero commercial content strategy.
Strategy development creates a content architecture organized by audience and buying stage. Investor content focuses on market opportunity, competitive differentiation, and commercial readiness — published consistently between funding rounds to maintain interest. Physician content positions your science within clinical practice context, building familiarity before commercial launch. Partner content demonstrates platform potential and collaboration value.
Execution builds a sustainable content engine with regulatory-compliant workflows. We establish clear content categories — educational vs. promotional — with appropriate review tracks for each. Educational thought leadership moves through streamlined review. Promotional content follows full MLR. This separation lets you publish consistently without compromising compliance. Our team produces the content; your experts review for scientific accuracy.
Measurement connects content performance to commercial outcomes. We track investor engagement (deck requests, meeting conversions after content exposure), physician awareness (KOL engagement, conference follow-up quality), and partnership interest. Content marketing in biotech isn't measured by page views — it's measured by the quality of conversations it creates.
What we deliver
- Content strategy framework — audience-segmented editorial calendar with regulatory workflow
- Thought leadership program — executive-authored content positioning your leadership team as authorities
- Investor content series — market analysis, competitive positioning, and commercial vision pieces
- Physician education content — clinical context pieces that build familiarity with your approach
The biotech companies that commercialize fastest aren't the ones with the best data — they're the ones who spent two years building the narrative before the data matured. Content marketing is how you win the market before you win the trial.
Our Methodology
Our 90-day content marketing sprint for biotech starts with audience mapping and regulatory workflow design. Phase one identifies the content gaps across investor, physician, and partner audiences. We audit competitor content strategies and map the topics where your company should own the conversation. Critically, we also design the regulatory review workflow — separating educational content (fast-track review) from promotional content (full MLR) to eliminate the bottleneck that kills most biotech content programs.
Phase two develops the editorial strategy and begins production. We create content templates for each audience segment, establish a publishing cadence, and produce the first wave of content. Our team handles writing and optimization; your experts provide 30-minute interviews that we transform into polished thought leadership.
Phase three scales production and establishes measurement. By month three, you should have a functioning content engine producing 4-8 pieces per month across audience segments. We track engagement quality metrics — not vanity metrics — connecting content exposure to investor meetings, KOL conversations, and partnership inquiries.
How We Work
Content marketing engagements for biotech companies typically run 6-12 months. The first 30 days focus on strategy, audience research, and regulatory workflow design. We interview your leadership, review competitor content, and establish the editorial framework and compliance processes.
Days 31-90 are the production ramp. We produce initial content across priority audience segments while refining the editorial process. Your subject matter experts participate in brief interviews (30-45 minutes each) that we develop into full articles, whitepapers, and thought leadership pieces. Regulatory review processes get tested and optimized during this phase.
Months 4-12 are steady-state production with ongoing optimization. Content cadence stabilizes at 4-8 pieces per month. We continuously refine topics based on engagement data and adjust the mix across investor, physician, and partner audiences based on commercial priorities.
Weekly editorial check-ins keep production on schedule. Monthly strategy reviews analyze content performance against commercial metrics. Quarterly deep-dives reassess audience priorities and competitive content landscape.
- Investor mindshare — consistent visibility between funding rounds that maintains valuation momentum
- Physician familiarity — pre-launch awareness that accelerates commercial adoption
- Content velocity — sustainable publishing cadence within regulatory compliance frameworks
If your biotech & pharma company needs content marketing leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does content marketing cost for biotech companies?
Monthly retainers typically range from $15K-$35K depending on content volume, audience segments, and production complexity. This covers strategy, writing, editing, regulatory workflow management, and performance analytics. Compared to hiring a content team in-house ($300K+ annually for writer, editor, and strategist), a fractional content marketing engagement delivers expertise across all audience segments at a fraction of the cost.
How do you handle regulatory review without killing content velocity?
We design parallel review tracks from day one. Educational and thought leadership content follows a streamlined review process with scientific accuracy checks. Promotional content with specific claims goes through full medical-legal review. This separation — which is well-established in regulatory practice — lets you publish educational content weekly while promotional materials follow appropriate timelines. Most clients see 3x improvement in content velocity within 60 days.
How long before content marketing produces measurable results for biotech?
Initial audience engagement improvements appear within 60-90 days — better investor meeting preparation, increased website engagement from target physicians, and growing organic visibility. Commercial pipeline influence becomes measurable at the 6-month mark. The real value of biotech content marketing compounds over 12-18 months as your thought leadership library becomes a persistent asset that works across every commercial conversation.
What makes Winston Francois different from healthcare content agencies?
Most healthcare content agencies produce technically accurate but commercially inert content. We build content strategies that drive commercial outcomes — investor meetings, physician awareness, partnership conversations. Our team combines life science knowledge with growth marketing expertise, meaning every piece of content serves a measurable business objective, not just a publishing calendar.
How do you measure content marketing ROI in biotech?
We track audience-specific engagement metrics: investor deck requests and meeting conversions, physician content consumption and KOL engagement rates, and partnership inquiry quality. We also monitor organic search visibility, AI citation frequency, and content-influenced pipeline. Vanity metrics like page views are secondary to the commercial conversations your content creates.
What type of biotech company is the right fit for content marketing?
Series A through commercial-stage companies with a clear therapeutic thesis and at least one audience that needs sustained engagement — investors between rounds, physicians before launch, or partners evaluating platform potential. If you're pre-Series A with no clinical data, content marketing is premature. The first step is a content audit to assess your current positioning gaps across key audiences.
